CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 疗法毒性：巨噬细胞在毒性发生中的重要性及潜在管理靶点
英文原题：CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management.
查看英文原题
CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年间，CAR-T 细胞疗法已崭露头角，其适应症不断增加，已有数款产品获批用于大B细胞非霍奇金淋巴瘤的二线治疗。其主要毒性为细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）。这些病症涉及一种高炎症级联反应，该反应通过单核吞噬细胞系统（MPS）被放大。本文综述了与CAR治疗相关的免疫介导不良事件，包括其病理生理学及当前治疗方法。我们特别讨论了MPS在CAR-T 疗法毒性和疗效中日益显现的作用，以及通过调控MPS以优化疗效同时最小化毒性的可能途径。
展开英文摘要原文
CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS). These entities involve a hyperinflammatory cascade which is amplified through the mononuclear phagocytic system (MPS).
Herein, we review the immune mediated adverse events related to CAR therapy, including their pathophysiologies, and current therapies. In particular, we discuss the emerging role of the MPS in both the toxicity and efficacy of CAR-T therapy, and possible avenues for the modulation of the MPS to optimize efficacy while minimizing toxicity.
论文信息
- 作者
- Norton J、Stiff P
- 单位
- Internal Medicine Department, Division of Hematology, Oncology, and Transplant, University of Minnesota, 516 Delaware Street SE, PWB 14-100, Minneapolis, MN, 55455, USA. Norto491@umn.edu.United States
- 文献类型
- 综述
- 期刊
- Discover oncology2025 Jan 15
- 原文标识
- PubMed 39812904 · DOI 10.1007/s12672-025-01776-0
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →